NASDAQ:KNSA Kiniksa Pharmaceuticals International Q3 2025 Earnings Report $38.33 +0.21 (+0.54%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Kiniksa Pharmaceuticals International EPS ResultsActual EPSN/AConsensus EPS $0.31Beat/MissN/AOne Year Ago EPSN/AKiniksa Pharmaceuticals International Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKiniksa Pharmaceuticals International Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, October 28, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Kiniksa Pharmaceuticals International Earnings HeadlinesKiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rating Lowered by Wall Street ZenOctober 5 at 2:46 AM | americanbankingnews.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Earns Buy Rating from Analysts at TD CowenSeptember 30, 2025 | americanbankingnews.comThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.October 8 at 2:00 AM | Brownstone Research (Ad)What Analysts Are Saying About Kiniksa Pharmaceuticals StockSeptember 30, 2025 | benzinga.comKiniksa Pharmaceuticals International, Plc (KNSA) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comSee More Kiniksa Pharmaceuticals International Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiniksa Pharmaceuticals International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals International and other key companies, straight to your email. Email Address About Kiniksa Pharmaceuticals InternationalKiniksa Pharmaceuticals International (NASDAQ:KNSA), Inc. is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies. The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome. Beyond Ilaris, Kiniksa’s clinical pipeline includes mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor being investigated for giant cell arteritis; remibrutinib, a selective BTK inhibitor in Phase III studies for chronic spontaneous urticaria; and pozelimab, an anti-C5 monoclonal antibody under development for rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis. Kiniksa operates globally, with commercial and development activities spanning North America, Europe and Asia under various licensing and distribution arrangements. The company is led by Founder and Chief Executive Officer John H. Johnson, who oversees a management team composed of experienced biopharmaceutical executives and scientific leaders. By combining strategic partnerships, disciplined capital allocation and a targeted R&D strategy, Kiniksa aims to deliver therapies that can transform the treatment landscape for patients with serious immune diseases.View Kiniksa Pharmaceuticals International ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
